software and brings artificial intelligence and microfluidic imaging technologies together in biopharmaceutical production. We identify protein aggregation, batch variation and anomalies during the manufacturing process, enabling better control of biologic drug product quality. Our technology develops ‘fingerprints’ that quantitatively characterize protein drug production and protein aggregates under different stressors. These fingerprints are used to identify and resolve production issues at-line.
How does your company control protein aggregation?